Eleclazine + Placebo
Phase 2/3Terminated 0 watching 0 views this week📈 Rising
64
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Hypertrophic Cardiomyopathy
Conditions
Hypertrophic Cardiomyopathy
Trial Timeline
Feb 5, 2015 → Feb 17, 2017
NCT ID
NCT02291237About Eleclazine + Placebo
Eleclazine + Placebo is a phase 2/3 stage product being developed by Gilead Sciences for Hypertrophic Cardiomyopathy. The current trial status is terminated. This product is registered under clinical trial identifier NCT02291237. Target conditions include Hypertrophic Cardiomyopathy.
Hype Score Breakdown
Clinical
22
Activity
15
Company
9
Novelty
7
Community
8
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02365506 | Phase 1 | Completed |
| NCT02291237 | Phase 2/3 | Terminated |
Competing Products
20 competing products in Hypertrophic Cardiomyopathy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Mavacamten | LianBio | Phase 1 | 25 |
| Mavacamten + Placebo | LianBio | Phase 3 | 69 |
| CT-G20 + Placebo | Celltrion | Phase 1 | 33 |
| candesartan | AstraZeneca | Phase 2 | 52 |
| LCZ696 + Placebo | Novartis | Phase 2 | 52 |
| Ranolazine | Gilead Sciences | Approved | 84 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| PF-06473871 + PF-06473871 | Pfizer | Phase 2 | 51 |
| EXC 001 + EXC 001 + EXC 001 + EXC 001 | Pfizer | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Approved | 84 |
| MYK-224 | Bristol Myers Squibb | Phase 2 | 51 |
| mavacamten | Bristol Myers Squibb | Phase 2/3 | 64 |
| mavacamten | Bristol Myers Squibb | Phase 2 | 51 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten | Bristol Myers Squibb | Pre-clinical | 22 |
| Mavacamten + Placebo | Bristol Myers Squibb | Phase 3 | 76 |